In Vitro Efficacy of Antiviral Agents against Omicron Subvariant BA.4.6

Emi Takashita; Seiya Yamayoshi; Peter Halfmann; Nancy Wilson; Hunter Ries; Alex Richardson; Max Bobholz; William Vuyk; Robert Maddox; David A. Baker; Thomas C. Friedrich; David H. O’Connor; Ryuta Uraki; Mutsumi Ito; Yuko Sakai-Tagawa; Eisuke Adachi; Makoto Saito; Michiko Koga; Takeya Tsutsumi; Kiyoko Iwatsuki-Horimoto; Maki Kiso; Hiroshi Yotsuyanagi; Shinji Watanabe; Hideki Hasegawa; Masaki Imai; Yoshihiro Kawaoka

Journal ArticleOPEN ACCESS

In Vitro Efficacy of Antiviral Agents against Omicron Subvariant BA.4.6

Takashita E
Yamayoshi S
Halfmann P
et al.

New England Journal of Medicine (2022) 387(22) 2094-2097

DOI: 10.1056/nejmc2211845

24Citations

27Readers

Abstract

Efficacy of Antiviral Agents against Omicron BA.4.6 Researchers report that antiviral agents remdesivir, molnupiravir, and nirmatrelvir and monoclonal antibodies bebtelovimab and imdevimab retain effectiveness against the BA.4.6 subvariant in vitro.

Cite

CITATION STYLE

APA

Takashita, E., Yamayoshi, S., Halfmann, P., Wilson, N., Ries, H., Richardson, A., … Kawaoka, Y. (2022). In Vitro Efficacy of Antiviral Agents against Omicron Subvariant BA.4.6. New England Journal of Medicine, 387(22), 2094–2097. https://doi.org/10.1056/nejmc2211845

In Vitro Efficacy of Antiviral Agents against Omicron Subvariant BA.4.6

Abstract

Cite

Register to see more suggestions